SEVERE WX : Air Stagnation Advisory View Alerts
STREAMING NOW: Watch Now

FDA approves new osteoporosis drug for postmenopausal women

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures.The F...

Posted: Apr 10, 2019 3:29 AM

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures.

The FDA announced Tuesday that the drug, called romosozumab, which has the brand name Evenity, works mainly by boosting bone formation and is approved to treat osteoporosis in women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have not benefited from other types of osteoporosis therapies.

"Today's approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk," Dr. Hylton V. Joffe, director of the FDA Center for Drug Evaluation and Research's Division of Bone, Reproductive and Urologic Products, said in the announcement.

"But Evenity may increase the risk of heart attack, stroke and cardiovascular death so it's important to carefully select patients for this therapy, which includes avoiding use in patients who have had a heart attack or stroke within the previous year," he said.

The drug was developed by the pharmaceutical companies Amgen and UCB, which worked together on development since 2004.

It is expected to be available from select wholesalers in the United States for physicians to order in about a week, at which time the price will be made publicly available, Amgen spokeswoman Kristen Davis wrote in an email Tuesday.

The FDA noted that one dose of Evenity is administered as two back-to-back injections given once a month by a health care professional. No more than 12 doses should be used, so if treatment is still needed after 12 months, other types are encouraged.

"The FDA approval of Evenity represents an important therapeutic development for patients who need a medicine that can rapidly increase bone mineral density and help reduce the risk of future fractures within 12 months," Dr. David M. Reese, executive vice president of research and development at Amgen, said in a news release Tuesday.

"Postmenopausal osteoporosis is a significant women's health issue that far too often gets overlooked. As a leader in bone health with more than 20 years of osteoporosis research experience, Amgen is as committed as ever to combatting this disease to help women at high risk for fracture reduce their risk of a first and subsequent fracture," he said.

The safety and efficacy of Evenity were tested in two clinical trials involving more than 11,000 women with postmenopausal osteoporosis, according to the FDA.

Although the trials found the drug to be effective in lowering the risk of a new fracture, the agency noted that there were some side effects, including an increased risk of cardiovascular death, heart attack and stroke.

The drug packaging comes with a "boxed warning" stating those risks and that the treatment should not be used in patients who have had a heart attack or stroke within the previous year. Other side effects of Evenity include joint pain and headache, and possible reactions or discomfort at the injection sites.

Osteoporosis is a disease that involves low bone mass and deterioration of bone tissue, leading to an increased risk of bone fractures, such as those of the hip, spine and wrist. Of the estimated 10 million people in the United States with osteoporosis, more than 80% are thought to be women.

Oregon Coronavirus Cases

Data is updated nightly.

Cases: 392197

Reported Deaths: 5186
CountyCasesDeaths
Multnomah60432839
Washington42082398
Marion39986507
Clackamas32861382
Lane30179358
Jackson24956361
Deschutes23639185
Umatilla15135182
Linn14704179
Douglas13438292
Josephine10201246
Yamhill9787143
Klamath9072147
Polk8248102
Benton611138
Malheur592790
Coos5693107
Columbia433356
Jefferson420866
Lincoln363852
Union339255
Crook336356
Wasco317046
Clatsop262735
Baker220833
Tillamook217045
Hood River214537
Morrow197825
Curry192439
Harney119933
Grant108515
Lake105616
Wallowa76013
Sherman1913
Gilliam1854
Wheeler1141
Unassigned00

California Coronavirus Cases

Data is updated nightly.

Cases: 5087907

Reported Deaths: 74561
CountyCasesDeaths
Los Angeles152858627184
San Diego4074794340
Riverside3880835358
San Bernardino3748555967
Orange3346265736
Sacramento1684922447
Kern1578751804
Fresno1568972259
Santa Clara1522681929
Alameda1252361507
San Joaquin1076041834
Ventura1040841191
Contra Costa1038691046
Stanislaus915481417
Tulare861371099
San Francisco56931672
San Mateo56354629
Monterey52521626
Solano47693358
Santa Barbara47345553
Merced45086668
Sonoma43207412
Placer42204470
Imperial38516773
Kings35221362
San Luis Obispo31511360
Madera26233311
Shasta26113458
Butte25476318
Santa Cruz22268224
Yolo21590260
Marin18495249
El Dorado18325166
Sutter14577186
Napa13424105
Yuba1076389
Tehama10282130
Humboldt10183119
Nevada10029105
Mendocino857799
Lassen797656
San Benito782979
Tuolumne774691
Lake7046110
Amador578366
Siskiyou475855
Glenn457436
Calaveras442288
Del Norte376942
Colusa325921
Inyo256746
Plumas19397
Mono18924
Mariposa160718
Trinity99817
Modoc7725
Sierra2180
Alpine1080
Unassigned810
Out of CA00
Medford
Cloudy
44° wxIcon
Hi: 46° Lo: 38°
Feels Like: 44°
Brookings
Partly Cloudy
55° wxIcon
Hi: 57° Lo: 47°
Feels Like: 55°
Crater Lake
Partly Cloudy
44° wxIcon
Hi: 46° Lo: 34°
Feels Like: 44°
Grants Pass
Cloudy
44° wxIcon
Hi: 47° Lo: 41°
Feels Like: 44°
Klamath Falls
Partly Cloudy
48° wxIcon
Hi: 54° Lo: 30°
Feels Like: 48°
More developing valley fog tonight
KDRV Radar
KDRV Fire Danger
KDRV Weather Cam

Community Events